Damora Therapeutics Reports Third-Quarter 2026 Financial Results
The company also said the CLARITY-101 Phase 1/1b clinical trial was initiated and cleared by multiple global regulatory authorities.
Story updates
09:14:14 PM UTC
SquawkNews
CLARITY-101 Phase 1/1b clinical trial initiated and cleared by multiple global regulatory authorities, includingthe U.S. Food and Drug Administration (FDA) ---- New preclinical data highlighting DMR-001’s potentially best-in-class pan-mutant CALR (mutCALR) activityto be presented at the American…
09:14:23 PM UTC
SquawkNews
Damora Therapeutics reported $528.5M in cash, cash equivalents and marketable securities as of September 30, 2026, which it expects to fund operations into 2H 2029. Q3 net loss was $32.0M versus $3.1M a year earlier.Material DetailsContext by AI AnalystThis is an early-stage biotech update combinin…